Skip to main content

PLXNB2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 14 bp deletion in exon 3 and 1 bp deletion in exon 3 and 34 bp deletion in exon 3.

Be the first to review this product! Submit a review

Images

Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (AB265412), expandable thumbnail
  • Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (AB265412), expandable thumbnail
  • Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (AB265412), expandable thumbnail
  • Western blot - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (AB265412), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 14 bp deletion in exon 3 and 1 bp deletion in exon 3 and 34 bp deletion in exon 3

Recommended products

PLXNB2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 14 bp deletion in exon 3 and 1 bp deletion in exon 3 and 34 bp deletion in exon 3.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 14 bp deletion in exon 3 and 1 bp deletion in exon 3 and 34 bp deletion in exon 3
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
PLXNB2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Cell culture

Biosafety level
EU: 2 US: 2
Viability
~ 80%
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.

Recommended control: Human wild-type HeLa cell line (ab271142). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

Cryopreservation cell medium: Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Culture medium:  DMEM (High Glucose) + 10% FBS  

Initial handling guidelines:

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.

2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.

3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.

4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.

5. Once confluent passage into an appropriate flask at a density of 2x10E4 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.  

Subculture guidelines:

• All seeding densities should be based on cell counts gained by established methods.

• A guide seeding density of 2x10E4 cells/cm2 is recommended.

• Cells should be passaged when they have achieved 80-90% confluence.

• Do not allow the cell density to exceed 7x10E4 cells/cm2.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Plexin B2 also known as PLXNB2 or MM1 is a high-molecular-weight protein approximately 220 kDa found in humans. Plexin B2 is involved in the semaphorin receptor complex and is made of multiple domains that interact with semaphorin molecules to mediate cellular functions. Plexin B2 is expressed in various tissues including the brain spinal cord and bones indicating its role in different neural and structural processes. This protein interacts with other members of the Plexin family and undergoes changes that allow it to serve numerous signaling roles in the body.

Biological function summary

Plexin B2 plays a role in cellular signaling processes that are essential for neural patterning and tissue morphogenesis. It binds with semaphorins particularly Sema4C to guide axonal repulsion in neural development. Plexin B2 forms part of a receptor complex that helps cells interpret external semaphorin signals influencing cell movement and positioning. These interactions contribute to the remodeling of neural circuits which is important during both prenatal development and adult neural function.

Pathways

Plexin B2 participates in pathways engaging Rho GTPases which are important for cytoskeletal organization and cell movement. Plexin B2 influences the RhoA and Rac1 pathways impacting actin cytoskeleton dynamics and cell adhesion processes. These pathways where Plexin B2 acts with other Rho family proteins help transmit the changes induced by semaphorin binding altering cellular orientation and migration.

Associated diseases and disorders

Plexin B2 has connections to neural tube defects and certain cancers. Defective Plexin B2 signaling can lead to improper neural tube closure contributing to conditions like spina bifida. Additionally in oncology the dysregulation of Plexin B2 expression or function links to tumor invasiveness and metastasis where it might interact with proteins like MET and Rho GTPases to influence cancer cell behavior. Understanding its role in these disorders aids in developing therapeutic strategies targeting aberrant Plexin B2 signaling.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

  • Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412), expandable thumbnail

    Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412)

    Allele-1: 1 bp deletion in exon 3.

  • Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412), expandable thumbnail

    Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412)

    Allele-2: 34 bp deletion in exon 3.

  • Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412), expandable thumbnail

    Sanger Sequencing - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412)

    Allele-3: 14 bp deletion in exon 3.

  • Western blot - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412), expandable thumbnail

    Western blot - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412)

    Blocking and diluting buffer and concentration: 5% NFDM/TBST.

    The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 25762646).

    In Western blot, Anti-Plexin B2/MM1 antibody [EPR29380-584] ab323571 was shown to bind specifically to Plexin B2/MM1. Target of interest was observed at 170, 240 kDa in wild-type HeLa cell lysates (lane 3)( (lane 3, wild-type cell line ab255928)) with no signal observed at this size in Plexin B2/MM1 knockout cell line (lane 4) (lane 4, knockout cell line ab265412).

    In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.

    All lanes: Western blot - Anti-Plexin B2/MM1 antibody [EPR29380-584] (Anti-Plexin B2/MM1 antibody [EPR29380-584] ab323571) at 1/1000 dilution

    Lane 1: HeLa (human cervical adenocarcinoma epithelial cell) transfected with scrambled siRNA control whole cell lysate at 20 µg

    Lane 2: HeLa transfected with siRNA specifically targeting Plexin B2/MM1 whole cell lysate at 20 µg

    Lane 3: Western blot - Human wild-type HeLa cell line (ab255928) at 20 µg

    Lane 4: Western blot - Human PLXNB2 (Plexin B2/MM1) knockout HeLa cell line (ab265412) at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution

    Observed band size: 170,240 kDa, 36 kDa

    Exposure time: 15s

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com